Midlife Insulin Resistance as a Predictor for Late-Life Cognitive Function and Cerebrovascular Lesions.
11C-PIB
APOE
Alzheimer’s disease
PET scan
amyloid
cerebrovascular lesions
cognition
follow-up study
insulin resistance
magnetic resonance
imaging
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
29
9
2019
medline:
6
11
2020
entrez:
29
9
2019
Statut:
ppublish
Résumé
Type 2 diabetes (T2DM) increases the risk for Alzheimer's disease (AD) but not for AD neuropathology. The association between T2DM and AD is assumed to be mediated through vascular mechanisms. However, insulin resistance (IR), the hallmark of T2DM, has been shown to associate with AD neuropathology and cognitive decline. To evaluate if midlife IR predicts late-life cognitive performance and cerebrovascular lesions (white matter hyperintensities and total vascular burden), and whether cerebrovascular lesions and brain amyloid load are associated with cognitive functioning. This exposure-to-control follow-up study examined 60 volunteers without dementia (mean age 70.9 years) with neurocognitive testing, brain 3T-MRI and amyloid-PET imaging. The volunteers were recruited from the Finnish Health 2000 survey (n = 6062) to attend follow-up examinations in 2014-2016 according to their insulin sensitivity in 2000 and their APOE genotype. The exposure group (n = 30) had IR in 2000 and the 30 controls had normal insulin sensitivity. There were 15 APOEɛ4 carriers per group. Statistical analyses were performed with multivariable linear models. At follow-up the IR+group performed worse on executive functions (p = 0.02) and processing speed (p = 0.007) than the IR- group. The groups did not differ in cerebrovascular lesions. No associations were found between cerebrovascular lesions and neurocognitive test scores. Brain amyloid deposition associated with slower processing speed. Midlife IR predicted poorer executive functions and slower processing speed, but not cerebrovascular lesions. Brain amyloid deposition was associated with slower processing speed. The association between midlife IR and late-life cognition might not be mediated through cerebrovascular lesions measured here.
Sections du résumé
BACKGROUND
Type 2 diabetes (T2DM) increases the risk for Alzheimer's disease (AD) but not for AD neuropathology. The association between T2DM and AD is assumed to be mediated through vascular mechanisms. However, insulin resistance (IR), the hallmark of T2DM, has been shown to associate with AD neuropathology and cognitive decline.
OBJECTIVE
To evaluate if midlife IR predicts late-life cognitive performance and cerebrovascular lesions (white matter hyperintensities and total vascular burden), and whether cerebrovascular lesions and brain amyloid load are associated with cognitive functioning.
METHODS
This exposure-to-control follow-up study examined 60 volunteers without dementia (mean age 70.9 years) with neurocognitive testing, brain 3T-MRI and amyloid-PET imaging. The volunteers were recruited from the Finnish Health 2000 survey (n = 6062) to attend follow-up examinations in 2014-2016 according to their insulin sensitivity in 2000 and their APOE genotype. The exposure group (n = 30) had IR in 2000 and the 30 controls had normal insulin sensitivity. There were 15 APOEɛ4 carriers per group. Statistical analyses were performed with multivariable linear models.
RESULTS
At follow-up the IR+group performed worse on executive functions (p = 0.02) and processing speed (p = 0.007) than the IR- group. The groups did not differ in cerebrovascular lesions. No associations were found between cerebrovascular lesions and neurocognitive test scores. Brain amyloid deposition associated with slower processing speed.
CONCLUSION
Midlife IR predicted poorer executive functions and slower processing speed, but not cerebrovascular lesions. Brain amyloid deposition was associated with slower processing speed. The association between midlife IR and late-life cognition might not be mediated through cerebrovascular lesions measured here.
Identifiants
pubmed: 31561373
pii: JAD190691
doi: 10.3233/JAD-190691
pmc: PMC6839606
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
215-228Références
Psychiatry Clin Neurosci. 2015 Oct;69(10):620-9
pubmed: 25781474
Neurology. 2010 Aug 31;75(9):764-70
pubmed: 20739649
Intern Med J. 2012 May;42(5):484-91
pubmed: 22372522
Alzheimers Dement. 2015 May;11(5):504-510.e1
pubmed: 25043908
Neurology. 1989 Sep;39(9):1159-65
pubmed: 2771064
Diabetologia. 2015 Nov;58(11):2545-53
pubmed: 26276262
Neuroimage Clin. 2016 Mar 05;11:435-449
pubmed: 27104138
JAMA. 1997 Mar 12;277(10):813-7
pubmed: 9052711
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Alzheimers Dement. 2012 Oct;8(5 Suppl):S88-95.e1
pubmed: 22682962
J Gerontol A Biol Sci Med Sci. 2009 Jan;64(1):118-24
pubmed: 19164275
Neurobiol Aging. 2010 Aug;31(8):1275-83
pubmed: 20472326
Neurology. 2015 Jun 9;84(23):2329-37
pubmed: 25948725
Lancet Neurol. 2013 Apr;12(4):357-67
pubmed: 23477989
Brain. 2008 Mar;131(Pt 3):665-80
pubmed: 18263627
Front Aging Neurosci. 2017 May 03;9:118
pubmed: 28515688
J Alzheimers Dis. 2017;57(4):1325-1334
pubmed: 28372335
Ann Neurol. 2000 Feb;47(2):145-51
pubmed: 10665484
Front Aging Neurosci. 2015 Jun 16;7:115
pubmed: 26136682
J Clin Invest. 2012 Apr;122(4):1316-38
pubmed: 22476197
JAMA Neurol. 2013 Apr;70(4):455-61
pubmed: 23420027
Cogn Neurosci. 2011 Jan 1;2(1):1-10
pubmed: 22792129
BMJ. 1997 Oct 25;315(7115):1045-9
pubmed: 9366728
Neurology. 2010 Nov 30;75(22):1982-7
pubmed: 21115952
Stroke. 2016 Dec;47(12):2938-2944
pubmed: 27827330
Dement Geriatr Cogn Disord. 2002;14(2):77-83
pubmed: 12145454
Neurology. 2018 Mar 27;90(13):e1150-e1157
pubmed: 29476033
J Lipid Res. 2004 Dec;45(12):2303-9
pubmed: 15342679
BMJ. 2010 Jul 26;341:c3666
pubmed: 20660506
Eur Radiol. 2019 Sep;29(9):4937-4947
pubmed: 30796570
Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1651-60
pubmed: 19495749
Semin Nucl Med. 2017 Jan;47(1):75-88
pubmed: 27987560
Arch Neurol. 1993 Aug;50(8):818-24
pubmed: 8352667
PLoS One. 2018 Jan 30;13(1):e0191345
pubmed: 29381739
Diabetes Care. 2017 Jun;40(6):751-758
pubmed: 28381479
Neurobiol Aging. 2017 Sep;57:84-94
pubmed: 28605642
Lancet Neurol. 2016 Apr;15(5):455-532
pubmed: 26987701
Nutrition. 1997 Jan;13(1):65; discussion 64, 66
pubmed: 9058458
J Alzheimers Dis. 2019;67(2):489-493
pubmed: 30594927
Alzheimers Dement. 2016 Aug;12(8):882-9
pubmed: 26812281
Nat Rev Neurol. 2018 Mar;14(3):168-181
pubmed: 29377010
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2019 Jun 14;:1-18
pubmed: 31198088
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
BMC Med. 2014 Nov 11;12:206
pubmed: 25385447
J Alzheimers Dis. 2017;60(3):1035-1043
pubmed: 28984587
Biochim Biophys Acta. 2016 May;1862(5):983-91
pubmed: 26657615
Stroke. 2015 Nov;46(11):3131-6
pubmed: 26451022
J Int Neuropsychol Soc. 2006 Sep;12(5):707-35
pubmed: 16961952
Stroke. 2006 Feb;37(2):466-70
pubmed: 16373631